[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Metanoic Health Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":73},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100600270","phase-2-safety-and-effectiveness-study-of-pre-operative-artesunate-in-stage-ii-iii-colorectal-cancer-100600270",false,"NCT07095309","Safety and Effectiveness Study of Pre-operative Artesunate in Stage II\u002F III Colorectal Cancer","Phase II Randomised, Double Blind, Placebo Controlled Trial of Neoadjuvant Artesunate in Stage II\u002FIII Colorectal Cancer","NeoART-M","Inclusion Criteria:\n\n* Aged 18 or over\n* Histologically proven single primary site colorectal adenocarcinoma or high grade dysplasia plus unequivocal radiological evidence of invasive cancer\n* Stage II\u002FIII colorectal cancer planned for surgical resection and no clinical indication for neoadjuvant preoperative chemotherapy\u002Fchemoradiation therapy\n* WHO performance status 0,1 or 2\n* Adequate full blood count: White Cell Count (WCC) \\>3.0 x 109 \u002Fl; Platelets \\>100 x 109\u002Fl; Haemoglobin (Hb) \\>80g\u002FL\n* Adequate renal function : Glomerular Filtration Rate \\>30ml\u002Fmin by Cockcroft-Gault formula.\n* Adequate hepatobiliary function : Total bilirubin \\\u003C 3 x Upper limit norm\n* Female participants of childbearing potential must have a negative pregnancy test \\\u003C72 hours prior to initiating study intervention and agree to avoid pregnancy using adequate, medically approved contraceptive precautions for up to 6 weeks after the last dose of study treatment interventions.\n* Male participants with a partner of childbearing potential must agree to use adequate, medically approved contraceptive precautions during and for up to 6 weeks after the last dose of the study treatment intervention.\n* Patient able and willing to provide written, informed consent for the study.\n\nExclusion Criteria:\n\n* Contraindication to use of artesunate due to hypersensitivity\n* Pregnancy or lactation\n* Male or female participants unwilling to use an effective method of birth control (either hormonal in the form of the contraceptive pill or barrier method of birth control accompanied by the use of a proprietary spermicidal foam\u002Fgel or film) ; or agreement of true abstinence from time consent is signed until 6 weeks after the last dose of study treatment intervention (i.e. withdrawal, calendar, ovulation, symptothermal and post ovulation are not acceptable methods)\n* History of hearing or balance problems\n* History of immunosuppression\n* Patient weight \\\u003C 52 kg or \\> 110 kg\n* Other planned intervention, apart from standard of care\n* Any other malignant disease diagnosis within the preceding 2 years with the exception of non-melanomatous skin cancer and carcinoma in situ\n* Lactose intolerance","ALL","18 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","TThis study evaluates the safety and effectiveness of pre-operative artesunate, given orally once a day for 14 days prior to surgery, in patients with Stage II\u002FIII colorectal cancer.\n\nArtesunate is an established antimalarial drug with an excellent safety profile. It is well tolerated, affordable, and widely available. Several laboratory studies and one small pilot clinical study in patients with colorectal cancer have shown that artesunate can reduce the proliferation and growth of cancer cells.\n\nOne hundred patients diagnosed with Stage II\u002FIII operable colorectal cancer will be randomly allocated to receive oral artesunate 200 mg daily or a matching placebo for 14 days prior to surgery. Patients will then be followed closely for 5 years to determine whether pre-operative artesunate reduces the risk of cancer recurrence after surgery.",[27,28],"Stage II\u002FIII Colon Cancer","Bowel Cancer",[30,31,32,33],"artesunate","colorectal","drug repurposing","antimalarial","NOT_YET_RECRUITING","2025-07-23",{"date":37,"type":38},"2025-07-31","ACTUAL",{"date":40,"type":21},"2025-08-15",{"date":42,"type":21},"2033-07-31",{"name":44,"class":45},"Metanoic Health Ltd.","INDUSTRY",6,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100600283","phase-2-safety-and-efficacy-of-oral-artesunate-for-pre-cervical-cancer-100600283","NCT07095478","Safety and Efficacy of Oral Artesunate for Pre-cervical Cancer","Phase II Single Arm, Open Label Study of Artesunate for the Treatment of Human Papilloma Virus Positive High Grade Cervical Intraepithelial Neoplasia (CIN2\u002F3)","NeoART-CIN","Inclusion Criteria:\n\n* Aged 18 or over\n* Histologically proven HPV positive cervical CIN2\u002F3\n* WHO performance status 0-2\n* Adequate full blood count:\n* White Cell Count (WCC) \\>3.0 x 109 \u002Fl;\n* Platelets \\>100 x 109\u002Fl;\n* Haemoglobin (Hb) \\>80g\u002FL\n* Adequate renal function:\n* Glomerular Filtration Rate \\>30ml\u002Fmin\n* Adequate hepatobiliary function:\n* Total bilirubin \\\u003C 3 x Upper limit normal\n* Female participants of child bearing potential must have a negative pregnancy test \\\u003C 72 hours prior to initiating study intervention and agree to avoid pregnancy using adequate, medically approved contraceptive precautions for up to 6 weeks after the last dose of study treatment intervention\n* Patient able and willing to provide written, informed consent for the study\n\nExclusion Criteria:\n\n* • Contraindication to the use of artesunate due to hypersensitivity\n\n  * Pregnancy or lactation\n  * Weight \\\u003C 52 kg\n  * History of previous CIN\n  * Immunocompromised patients","FEMALE",{"count":57,"type":21},28,[24],"NeoART-CIN is a Phase II clinical study evaluating the safety and effectiveness of oral artesunate in patients with pre-cancerous cervical intra-epithelial neoplasia (CIN2\u002F3), to investigate if a course of treatment with oral artesunate can reverse pre-cancerous changes in the cervix and prevent the development and progression of invasive cancer. Findings from this study will increase our understanding of the effects of artesunate on CIN2\u002F3 and if confirmatory inform future clinical studies.",[61],"CIN 2\u002F3",[63,64,32,65,33],"CIN","HPV","Artesunate",{"date":37,"type":38},{"date":68,"type":21},"2025-08-01",{"date":70,"type":21},"2028-06-30",{"name":44,"class":45},5,""]